2023
COVID-19 bacteremic co-infection is a major risk factor for mortality, ICU admission, and mechanical ventilation
Patton M, Orihuela C, Harrod K, Bhuiyan M, Dominic P, Kevil C, Fort D, Liu V, Farhat M, Koff J, Lal C, Gaggar A, Richter R, Erdmann N, Might M, Gaggar A. COVID-19 bacteremic co-infection is a major risk factor for mortality, ICU admission, and mechanical ventilation. Critical Care 2023, 27: 34. PMID: 36691080, PMCID: PMC9868503, DOI: 10.1186/s13054-023-04312-0.Peer-Reviewed Original ResearchConceptsBacterial co-infectionNeutrophil-to-lymphocyte ratioIn-hospital mortalityMechanical ventilationICU admissionCo-infectionRisk factorsSARS-CoV-2 variantsCohort studyIncreased riskPrimary outcomeIncreased risk of in-hospital mortalityRisk of in-hospital mortalityCommunity-acquired bacteremiaCulture-positive resultsRetrospective cohort studySingle-center reportsInpatient encountersMultivariate logistic regressionBlood culturesPrognostic indicatorOmicron SARS-CoV-2 variantComparison cohortOdds ratioSevere disease
2022
I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations
Files DC, Matthay MA, Calfee CS, Aggarwal NR, Asare AL, Beitler JR, Berger PA, Burnham EL, Cimino G, Coleman MH, Crippa A, Discacciati A, Gandotra S, Gibbs KW, Henderson PT, Ittner CAG, Jauregui A, Khan KT, Koff JL, Lang J, LaRose M, Levitt J, Lu R, McKeehan JD, Meyer NJ, Russell DW, Thomas KW, Eklund M, Esserman LJ, Liu KD, Esserman L, Calfee C, Liu K, Coleman M, Matthay M, Beitler J, Mittel A, Asare A, Yen A, Jauregui A, Crippa A, Suarez A, Serra A, Amin A, Rosen A, Dzierba A, Discacciati A, Haczku A, Barker A, Weisman A, Daniel B, Morrissey B, Ittner C, Jones C, Creel-Bulos C, Angelucci C, Files D, Russell D, Ng D, Burnham E, Youssef F, Chaparro-Rojas F, Harris G, Barot H, Su H, Garcia I, Sutter J, Dodin J, McKeehan J, Lee J, Kazianis J, Reilly J, Koff J, Detelich J, Lang J, Muir J, Thomas K, Khan K, Gosek K, Nugent K, Gibbs K, Yee K, Rodrigues L, Macias L, Orr L, Boerger L, Rosario-Remigio L, Kufa L, Huerta L, Tanios M, Reyes M, Eklund M, LaRose M, Adelman M, Juarez M, Jung M, Meyers M, Sternlieb M, Cobb N, Aggarwal N, Mangalmurti N, Meyer N, Jones P, Berger P, Henderson P, Saban P, Marshall P, Robinson P, Yang P, Madahar P, Nair R, Sonti R, Lee R, Wunderink R, Wahab R, Lupu R, Lu R, Kumar S, Auld S, Fields S, Wong F, Gandotra S, Pearson S, Whealon S, Albertson T, Obermiller T, Oliver T, Darmanian A, Schicchi J, Martinez E, Sarafian F, Nguyen J, Weiler-Lisowski B, Wyatt J, Blevins D, Melendrez M, Lopez B, Tzehaie H, Amosu O, Simonson A, Patel C, Levitt J, Hardy E, Lindgren B, Peterfreund G, Landreth L, Parks L, Aggarwal N. I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations. BMJ Open 2022, 12: e060664. PMID: 35667714, PMCID: PMC9170797, DOI: 10.1136/bmjopen-2021-060664.Peer-Reviewed Original ResearchConceptsSevere COVID-19COVID-19 trialsInvestigational agentsPlatform trialsCOVID-19 acute respiratory failureDefinitive efficacy trialAcute respiratory failureAdaptive platform trialPeer-reviewed medical journalsCOVID-19Novel effective therapeuticsCentral institutional review boardInstitutional review boardRespiratory failureIneffective therapyTherapeutic responseCommunity hospitalEfficacy trialsSerial studiesTrial designWake Forest SchoolEffective therapeuticsTrials NetworkPromising agentPatientsClinical trial design during and beyond the pandemic: the I-SPY COVID trial
Calfee C, Liu K, Asare A, Beitler J, Berger P, Coleman M, Crippa A, Discacciati A, Eklund M, Files D, Gandotra S, Gibbs K, Henderson P, Levitt J, Lu R, Matthay M, Meyer N, Russell D, Thomas K, Esserman L, Mittel A, Dzierba A, Madahar P, Serra A, Rosen A, Garcia I, Muir J, Schicchi J, Darmanian A, Wahab R, Gosek K, Auld S, Adelman M, Nugent K, Harris G, Creel-Bulos C, Yang P, Detelich J, Spainhour C, Cobb N, Sonti R, Orr L, Robinson P, Sarafian F, Martinez E, Jones P, Nguyen J, Obermiller T, Weiler-Lisowski B, Kufa L, Saba P, Wyatt J, Youssef F, Tanios M, Blevins D, Macias L, Suarez A, Reyes M, Jung M, Melendrez M, Rosario-Remigio L, Su H, Friedman E, Angelucci C, Chaparro-Rojas F, Sternlieb M, Sutter J, Whealon S, Nair R, Lopez B, Amosu O, Tzehaie H, Wunderink R, Patel C, Simonson A, Dodin J, Oliver T, Lupu R, Meyers M, Albertson T, Haczku A, Hardy E, Morrissey B, Juarez M, Pearson S, Lee R, Amin A, Jauregui A, Fields S, Ng D, Daniel B, Yee K, Jones C, Burnham E, McKeehan J, Ittner C, Reilly J, Mangalmurti N, Rodrigues L, Weisman A, Khan K, Wong S, Yen A, Peterfreund G, Kumar S, Marshall P, Huerta L, Lindgren B, Lee J, Barker A, Lang J, LaRose M, Landreth L, Parks L, Barot H, Koff J, Kazianis J, Boerger L. Clinical trial design during and beyond the pandemic: the I-SPY COVID trial. Nature Medicine 2022, 28: 9-11. PMID: 35058620, PMCID: PMC8922451, DOI: 10.1038/s41591-021-01617-x.Peer-Reviewed Original Research